Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 41

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 41
---
 pharmaceuticals, medical equipment, medical consumables and other supplies used in its operations, and cannot guarantee that the products in use are not defective or counterfeit. NewGenIvf also has no control over independent sub-contractors and cannot guarantee the services thereof. |
| ● | If NewGenIvf loses its relationship with one or more key pharmaceutical manufacturers, its business and results of operations could be adversely affected.                                                                                                                                                                                                                                                    |
| ● | NewGenIvf has engaged in transactions with related parties, and such transactions present potential conflicts of interest that could have an adverse effect on its business and results of operations.                                                                                                                                                                                                        |
| ● | NewGenIvf may be subject to claims and allegations relating to intellectual property and other causes.                                                                                                                                                                                                                                                                                                        |

| ● | Certain data and information in this prospectus relied on by NewGenIvf were obtained from third-party data and polls. These metrics were not independently verified by NewGenIvf and may not be accurate. |

Risks Related to Government Regulation

| ● | NewGenIvf operates in a highly regulated industry and must comply with a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits applicable to NewGenIvf’s business may have a material and adverse impact on NewGenIvf’s business, financial condition, and results of operations. |
| ● | Advertising or offering of gender selection services in certain jurisdictions in which NewGenIvf operates could expose NewGenIvf and its directors and executive officers to significant legal and regulatory risks, including potential penalties.                                                                                        |
| ● | Changes in NewGenIvf’s effective tax rate or tax liability may have an adverse effect on its results of operations.                                                                                                                                                                                                                        |
| ● | NewGenIvf’s reported financial results may be adversely affected by changes in accounting principles generally accepted in relevant jurisdictions.                                                                                                                                                                                         |
| ● | If NewGenIvf’s estimates or judgments relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely affected.                                                                                                                                                                           |
| ● | NewGenIvf is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it to criminal or civil liability and harm its business, financial condition and results of operations.                                                                                      |

<div align='center'>21</div>

Risks Related to this Best Efforts Offering

| ● | This is a best efforts offering, no minimum number or dollar amount of securities is required to be sold,